See more : Phoslock Environmental Technologies Limited (PET.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Yuyu Pharma, Inc. (000225.KS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Yuyu Pharma, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Shenzhen Hifuture Information Technology Co., Ltd. (002168.SZ) Income Statement Analysis – Financial Results
- Public Storage (PSA-PK) Income Statement Analysis – Financial Results
- Bio-Path Holdings, Inc. (BPTH) Income Statement Analysis – Financial Results
- Dynamic Holdings Limited (0029.HK) Income Statement Analysis – Financial Results
- Global Medical REIT Inc. (GMRE) Income Statement Analysis – Financial Results
Yuyu Pharma, Inc. (000225.KS)
About Yuyu Pharma, Inc.
Yuyu Pharma, Inc. develops and markets pharmaceutical products. The company offers various prescription drugs, including osteoporosis, brainbone metabolism-hypocalcemia improvement, cerebral and peripheral circulatory disturbance, tromboembolism, respiratory organ, hypertension, pulmonary tuberculosis therapy, arthrifuge, diabetic neuropathy therapy, eczematous dermatitis drugs, and other circulatory system drugs, as well as antibiotics and skeletal muscle relaxants. It also provides non-prescription drugs and health supplements. The company was formerly known as YuYu Inc. and changed its name to Yuyu Pharma, Inc. in May 2008. Yuyu Pharma, Inc. was founded in 1941 and is headquartered in Seoul, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 137.21B | 138.88B | 115.66B | 98.12B | 90.88B | 83.10B | 62.85B | 71.58B | 69.74B | 62.82B | 61.99B | 61.98B | 58.80B | 52.03B | 47.90B | 45.01B | 73.84B | 73.39B |
| Cost of Revenue | 88.68B | 85.57B | 70.32B | 52.85B | 44.27B | 42.46B | 32.87B | 38.21B | 38.87B | 31.72B | 29.62B | 26.63B | 25.56B | 21.24B | 21.04B | 18.08B | 26.31B | 26.15B |
| Gross Profit | 48.53B | 53.31B | 45.34B | 45.27B | 46.61B | 40.64B | 29.99B | 33.37B | 30.87B | 31.10B | 32.37B | 35.35B | 33.23B | 30.79B | 26.86B | 26.94B | 47.53B | 47.24B |
| Gross Profit Ratio | 35.37% | 38.39% | 39.20% | 46.14% | 51.29% | 48.90% | 47.71% | 46.62% | 44.27% | 49.51% | 52.22% | 57.04% | 56.52% | 59.18% | 56.07% | 59.84% | 64.37% | 64.37% |
| Research & Development | 7.19B | 8.62B | 4.01B | 4.12B | 876.67M | 1.42B | 1.69B | 2.25B | 1.25B | 1.13B | 999.22M | 845.13M | 922.65M | 487.55M | 1.42B | 1.02B | 2.85B | 3.13B |
| General & Administrative | 4.19B | 4.96B | 3.90B | 3.64B | 4.47B | 4.34B | 3.29B | 4.41B | 6.38B | 7.00B | 6.46B | 4.84B | 5.10B | 4.47B | 4.13B | 4.57B | 5.27B | 5.06B |
| Selling & Marketing | 11.71B | 15.04B | 12.47B | 10.49B | 11.59B | 10.75B | 7.16B | 8.04B | 6.67B | 7.22B | 8.28B | 11.65B | 11.92B | 10.52B | 9.53B | 12.50B | 12.40B | 10.09B |
| SG&A | 15.90B | 19.99B | 16.38B | 14.13B | 16.06B | 15.09B | 10.45B | 12.46B | 13.05B | 14.22B | 14.74B | 16.49B | 17.02B | 15.00B | 13.65B | 17.06B | 17.67B | 15.16B |
| Other Expenses | 0.00 | 25.29B | 23.75B | 20.74B | 21.60B | 322.19M | -183.72M | 255.42M | 1.06B | -6.65B | 645.91M | 64.87M | 40.28M | 1.01B | 562.15M | 1.93B | -7.17M | 312.79M |
| Operating Expenses | 47.25B | 53.91B | 44.14B | 39.00B | 38.54B | 35.31B | 26.42B | 29.64B | 29.26B | 29.73B | 30.62B | 31.64B | 31.13B | 29.50B | 26.27B | 32.67B | 37.53B | 34.17B |
| Cost & Expenses | 136.85B | 139.47B | 114.46B | 91.85B | 82.80B | 77.77B | 59.28B | 67.84B | 68.13B | 61.45B | 60.24B | 58.27B | 56.70B | 50.73B | 47.31B | 50.75B | 63.84B | 60.32B |
| Interest Income | 896.74M | 561.67M | 201.00M | 165.96M | 340.39M | 250.59M | 131.35M | 109.76M | 117.12M | 241.23M | 221.81M | 159.32M | 156.33M | 543.07M | 424.59M | 1.02B | 1.06B | 242.97M |
| Interest Expense | 2.55B | 2.58B | 2.18B | 1.76B | 1.79B | 1.12B | 380.96M | 427.84M | 296.91M | 303.62M | 255.59M | 246.25M | 431.57M | 561.17M | 1.19B | 2.10B | 2.05B | 1.75B |
| Depreciation & Amortization | 5.61B | 5.03B | 4.50B | 3.90B | 3.16B | 2.13B | 1.94B | 1.60B | 1.54B | 1.51B | 1.63B | 1.55B | 1.69B | 2.25B | 2.69B | 3.31B | 4.59B | 4.90B |
| EBITDA | 4.86B | 3.40B | 5.70B | 10.17B | 11.19B | 7.45B | 8.85B | 8.57B | 3.16B | -6.10B | 3.47B | 5.27B | 3.47B | 3.67B | 3.18B | -37.67M | 14.73B | 18.81B |
| EBITDA Ratio | 3.54% | 4.12% | 6.19% | 9.50% | 12.13% | 9.89% | 9.38% | 8.25% | 6.90% | -7.97% | 6.87% | 9.16% | 6.52% | 8.98% | 6.63% | 0.78% | 19.95% | 25.14% |
| Operating Income | 364.54M | 691.75M | 2.65B | 6.27B | 8.07B | 5.33B | 3.57B | 3.73B | 1.61B | 1.37B | 1.76B | 3.72B | 1.82B | 1.29B | 587.72M | -5.73B | 10.00B | 13.07B |
| Operating Income Ratio | 0.27% | 0.50% | 2.29% | 6.39% | 8.89% | 6.41% | 5.68% | 5.22% | 2.31% | 2.18% | 2.83% | 6.00% | 3.09% | 2.49% | 1.23% | -12.74% | 13.55% | 17.81% |
| Total Other Income/Expenses | -5.81B | -3.22B | -3.04B | -2.56B | -1.47B | -679.48M | -1.14B | 2.80B | -2.47B | -9.04B | 223.25M | -132.03M | -212.65M | -433.54M | 2.05B | 279.17M | 5.57B | -910.41M |
| Income Before Tax | -5.44B | -3.81B | -383.16M | 3.71B | 6.60B | 4.65B | 4.81B | 6.54B | -281.50M | -7.67B | 2.63B | 3.59B | 1.35B | 860.04M | 2.64B | -5.45B | 15.58B | 12.16B |
| Income Before Tax Ratio | -3.97% | -2.74% | -0.33% | 3.78% | 7.26% | 5.59% | 7.66% | 9.13% | -0.40% | -12.21% | 4.24% | 5.79% | 2.29% | 1.65% | 5.51% | -12.12% | 21.09% | 16.57% |
| Income Tax Expense | 98.44M | 615.02M | 537.13M | 1.30B | 1.04B | 336.12M | 524.75M | 391.28M | 122.19M | -309.23M | 697.76M | 600.25M | -560.06M | -257.23M | 364.57M | 232.74M | 2.01B | 3.60B |
| Net Income | -7.18B | -4.43B | -920.29M | 2.41B | 4.72B | 4.02B | 4.54B | 5.89B | -252.68M | -7.47B | 1.88B | 2.98B | 1.91B | 1.12B | 2.27B | -5.69B | 13.57B | 8.56B |
| Net Income Ratio | -5.23% | -3.19% | -0.80% | 2.46% | 5.20% | 4.84% | 7.23% | 8.22% | -0.36% | -11.89% | 3.03% | 4.81% | 3.24% | 2.15% | 4.75% | -12.63% | 18.37% | 11.66% |
| EPS | -441.41 | -266.90 | -57.67 | 194.34 | 377.83 | 281.50 | 406.00 | 493.50 | -25.45 | -746.43 | 178.00 | 301.00 | 161.00 | 106.50 | 218.00 | -452.98 | 1.04K | 652.50 |
| EPS Diluted | -441.41 | -266.90 | -57.67 | 194.34 | 376.31 | 281.50 | 400.00 | 493.50 | -25.45 | -746.43 | 176.50 | 301.00 | 161.00 | 106.50 | 218.00 | -452.98 | 1.04K | 652.50 |
| Weighted Avg Shares Out | 16.27M | 16.58M | 15.96M | 12.41M | 11.74M | 14.28M | 11.19M | 11.93M | 9.93M | 10.00M | 10.54M | 9.90M | 9.16M | 10.49M | 10.43M | 12.56M | 13.03M | 13.12M |
| Weighted Avg Shares Out (Dil) | 16.27M | 16.58M | 15.96M | 12.41M | 15.00M | 14.28M | 11.35M | 11.93M | 9.93M | 10.00M | 10.63M | 9.90M | 9.16M | 10.49M | 10.43M | 12.56M | 13.03M | 13.12M |
Source: https://incomestatements.info
Category: Stock Reports